These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 1727618)
1. The cause and pathogenesis of the eosinophilia-myalgia syndrome. Varga J; Uitto J; Jimenez SA Ann Intern Med; 1992 Jan; 116(2):140-7. PubMed ID: 1727618 [TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of L-tryptophan eosinophilia myalgia syndrome. Sternberg EM Adv Exp Med Biol; 1996; 398():325-30. PubMed ID: 8906284 [TBL] [Abstract][Full Text] [Related]
3. L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis. Varga J; Jimenez SA; Uitto J J Invest Dermatol; 1993 Jan; 100(1):97S-105S. PubMed ID: 8423409 [TBL] [Abstract][Full Text] [Related]
4. 1,1'-Ethylidenebis(tryptophan) (Peak E) induces functional activation of human eosinophils and interleukin 5 production from T lymphocytes: association of eosinophilia-myalgia syndrome with a L-tryptophan contaminant. Yamaoka KA; Miyasaka N; Inuo G; Saito I; Kolb JP; Fujita K; Kashiwazaki S J Clin Immunol; 1994 Jan; 14(1):50-60. PubMed ID: 8132737 [TBL] [Abstract][Full Text] [Related]
5. Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic. Takagi H; Ochoa MS; Zhou L; Helfman T; Murata H; Falanga V J Clin Invest; 1995 Nov; 96(5):2120-5. PubMed ID: 7593596 [TBL] [Abstract][Full Text] [Related]
6. Eosinophilia-myalgia syndrome: a recent syndrome serving as an alert to new diseases ahead. Sidransky H Mod Pathol; 1994 Sep; 7(7):806-10. PubMed ID: 7824518 [TBL] [Abstract][Full Text] [Related]
7. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology. Martin RW; Duffy J; Engel AG; Lie JT; Bowles CA; Moyer TP; Gleich GJ Ann Intern Med; 1990 Jul; 113(2):124-34. PubMed ID: 2360751 [TBL] [Abstract][Full Text] [Related]
8. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico. Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958 [TBL] [Abstract][Full Text] [Related]
9. Effect of L-tryptophan products on function of human eosinophils: investigation of the causal mechanisms of eosinophilia myalgia syndrome associated with L-tryptophan products. Saito H; Miyamoto T Int Arch Allergy Immunol; 1996; 111 Suppl 1():37-42. PubMed ID: 8906111 [TBL] [Abstract][Full Text] [Related]
11. Eosinophil-active cytokine from mononuclear cells cultured with L-tryptophan products: an unexpected consequence of endotoxin contamination. Kita H; Mayeno AN; Weyand CM; Goronzy JJ; Weiler DA; Lundy SK; Abrams JS; Gleich GJ J Allergy Clin Immunol; 1995 Jun; 95(6):1261-7. PubMed ID: 7797795 [TBL] [Abstract][Full Text] [Related]
12. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro. Zangrilli JG; Mayeno AN; Vining V; Varga J Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499 [TBL] [Abstract][Full Text] [Related]
13. A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan). Silver RM; Ludwicka A; Hampton M; Ohba T; Bingel SA; Smith T; Harley RA; Maize J; Heyes MP J Clin Invest; 1994 Apr; 93(4):1473-80. PubMed ID: 8163652 [TBL] [Abstract][Full Text] [Related]
14. ["Eosinophilia-myalgia" syndrome due to L-tryptophan containing products. Cooperative evaluation of French Regional Centers of Pharmacovigilance. Analysis of 24 cases]. Castot A; Bidault I; Bournerias I; Carlier P; Efthymiou ML Therapie; 1991; 46(5):355-65. PubMed ID: 1754978 [TBL] [Abstract][Full Text] [Related]
15. EBT, a tryptophan contaminant associated with eosinophilia myalgia syndrome, is incorporated into proteins during translation as an amino acid analog. Buss WC; Stepanek J; Bankhurst AD; Mayeno AN; Pastuszyn A; Peabody D Autoimmunity; 1996; 25(1):33-45. PubMed ID: 9161698 [TBL] [Abstract][Full Text] [Related]
16. L-tryptophan contaminant 'peak E' induces the release of IL-5 and IL-10 by peripheral blood mononuclear cells from patients with functional somatic syndromes. Barth H; Klein R; Berg PA Clin Exp Immunol; 2001 Nov; 126(2):187-92. PubMed ID: 11703359 [TBL] [Abstract][Full Text] [Related]
17. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. Slutsker L; Hoesly FC; Miller L; Williams LP; Watson JC; Fleming DW JAMA; 1990 Jul; 264(2):213-7. PubMed ID: 2355442 [TBL] [Abstract][Full Text] [Related]
18. [L-tryptophan and the eosinophilia-myalgia syndrome--consequences for artificial nutrition?]. Bässler KH Infusionstherapie; 1991 Feb; 18(1):5-10. PubMed ID: 1903129 [TBL] [Abstract][Full Text] [Related]
20. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. Hertzman PA; Blevins WL; Mayer J; Greenfield B; Ting M; Gleich GJ N Engl J Med; 1990 Mar; 322(13):869-73. PubMed ID: 2314421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]